Approval · Notice of Compliance 38293 · 2026
YERVOY: Notice of Compliance 38293
Issued September 16, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38293
- Date
- September 16, 2026
- Company
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indications and Product Monograph update: YERVOY (ipilimumab for injection) is indicated for: • Yervoy, in combination with nivolumab, is indicated for the first-line treatment of adult patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer. • Yervoy, in combination with nivolumab, is indicated forthe first-line treatment of adult patients with unresectable or advanced HCC.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| YERVOY | Not yet assigned | — |
Medicinal ingredients
- IPILIMUMAB 5 MG per ML